Human Insulin Market Growing at 10.29% CAGR to 2019

Aug 20, 2015, 06:00 ET from ReportsnReports

PUNE, India, August 20, 2015 /PRNewswire/ --

The Global Human Insulin Market 2015-2019 research report considers revenue generated from the sales of various drugs used in the treatment of diabetes to calculate the worldwide market size of human insulin for the study.

Complete report on human insulin market spread across 63 pages, talking about 3 major companies and supported with 23 data exhibits is now available at http://www.reportsnreports.com/reports/413136-global-human-insulin-market-2015-2019.html .

The key players in the human insulin market are extending their support to academic institutions for R&D of innovative products for diabetes care. For instance, Sanofi Diabetes collaborated with academic institutions such as Helmholtz Zentrum and Charite to support R&D in the diabetes care segment. The recent collaboration of Sanofi and Gubra to discover new targets for diabetes is based on the consortium between the University of Copenhagen, Gubra and Gentofte Hospital, which is partly funded by the Danish National Advanced Technology foundation. Such collaborations enable the amalgamation of research expertise of academic institutions with the marketing intelligence of pharma companies, which is expected to support the growth of the human insulin market.

According to this latest human insulin market report, diabetes is managed by the administration of insulin on a lifelong basis. However, insulin-based therapies are incapable of controlling blood glucose levels completely and are often associated with undesirable effects such as nocturnal hypoglycemia. During the fasting stage, glucose utilization increases and free fatty acid utilization decreases in the muscle cells, leading to hypoglycemia. In addition, fat breakdown decreases and fat storage increases in the liver cells, leading to weight gain. Severe hypoglycemic events and weight gain often result in poor patient compliance. Administered insulin therapies have lesser activity in liver and more activity in the periphery as compared to that of endogenous insulin. Therefore, there is a need to develop insulin therapies with better efficacy and safety profile, which is in turn driving the human insulin market growth. Further, the report states that the global industry is witnessing patent expiries for major brands.

Lilly, Novo Nordisk and Sanofi are the major companies analyzed in the global human insulin market 2015-2019 research report. Other prominent players simply mentioned in the research include Biocon, Biodel, Biogenomics, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, Diasome Pharmaceuticals, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals, Macrogenics, Merck, Oramed Pharmaceuticals, Osiris Therapeutics, Thermalin Diabetes, Tolerion, Wockhardt and XOMA. Order a copy of this human insulin market report at http://www.reportsnreports.com/Purchase.aspx?name=413136 .

For the human insulin market stakeholders, this report helps answer questions like what will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in human insulin market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?

The second study titled Global and Chinese Human Insulin Industry, 2009-2019 Market Research Report is spread across 150 pages and is a professional and in-depth study on the current state of the global Human Insulin industry with a focus on the Chinese market. The report provides key statistics on the market status of the Human Insulin manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. The report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2009-2014 market shares for each company. Through the statistical analysis, the report depicts the global and Chinese total market of Human Insulin industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export. The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2014-2019 market development trends of Human Insulin industry. Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Human Insulin Industry before evaluating its feasibility. Comprehensive table of contents and more on this human insulin market report is available at http://www.reportsnreports.com/reports/318140-global-and-chinese-human-insulin-industry-2009-2019-market-research-report.html .

For the pharmaceuticals market and its decision makers, ReportsnReports.com has multiple reports on the insulin sector as well as other related segments that might be of interest:

Insulin Market in Europe 2015-2019: According to this European insulin market research report, changing lifestyle, consumption of high-fat-containing foods, and reduced physical activity increase the prevalence of obesity among the population. Obesity affects the body's normal metabolism, triggering the adipose tissues to release increased amounts of fatty acids, hormones, pro-inflammatory cytokines, and other factors, which are involved in insulin resistance. Growing public awareness of diabetes and the available treatments will likely increase the number of people opting for treatments of these. Healthcare companies are organizing awareness camps and discussions to educate people about the condition. These are conducted either alone or in combination with other national institutes. Eli Lilly and Co., Novo Nordisk A/S, Sanofi SA, Biodel, Boehringer Ingelheim, Bristol-Myers Squibb, Diamyd Medical, DiaVacs, Pfizer, Generex Biotechnology, Lexicon Pharmaceuticals, Macrogenics, Merck, Osiris Therapeutics, Tolerion and XOMA are some of the companies mentioned in this report available at http://www.reportsnreports.com/reports/407806-insulin-market-in-europe-2015-2019.html .

Explore more research reports on insulin market at http://www.reportsnreports.com/tags/insulin-market-research.html .

About Us:  

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
sales@reportsandreports.com


SOURCE ReportsnReports